A Phase 2 Study of Galicaftor/Navocaftor/ABBV-119 Combination Therapy in Subjects with Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation.

Published: 23-09-2021
Last updated: 17-01-2025

Cystic Fibrosis (CF) is a rare, life-threatening, genetic disease that affects the lungs and digestive system, significantly impairing the quality of life, with those affected having a median age of death at 40.

Ethical review	Approved WMO
Status	Completed
Health condition type	Respiratory disorders congenital
Study type	Interventional

Summary

ID

NL-OMON49886

Source
ToetsingOnline

Brief title
M19-771

Condition

- Respiratory disorders congenital

Synonym
CF, mucoviscidosis

Research involving
Human

Sponsors and support

Primary sponsor: AbbVie Deutschland GmbH & Co. KG
Source(s) of monetary or material Support: AbbVie

Intervention

Keyword: Combination therapy, Corrector, Cystic Fibrosis, Potentiator

Outcome measures

Primary outcome

Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in

1 Second (ppFEV1).

Secondary outcome

1. Absolute change from Baseline in Sweat Chloride (SwCl).

2. Absolute change from Baseline in forced vital capacity [FVC].

3. Absolute change from Baseline in forced expiratory flow at mid-lung capacity

[FEF25-75].

4. Relative changes from Baseline in Percent Predicted Forced Expiratory Volume

in 1 Second (ppFEV1).

5. Relative changes from Baseline in forced vital capacity [FVC].

6. Relative changes from Baseline in Forced Expiratory Flow Between 25% and 75%

of Exhaled Volume (FEF25-75).

7. Absolute change in CF Questionnaire-Revised (CFQ-R) respiratory domain score

from Baseline.

Study description

Background summary

Cystic Fibrosis (CF) is a rare, life-threatening, genetic disease that affects the lungs and digestive system, significantly impairing the quality of life, with those affected having a median age of death at 40.

Study objective

Cystic Fibrosis (CF) is a rare, life-threatening, genetic disease that affects the lungs and digestive system, significantly impairing the quality of life, with those affected having a median age of death at 40.

Study design

Randomized, Double-blind, Parallel cohort study

Intervention

Participants in arm 1 will receive oral capsules of galicaftor/navocaftor dual combination for 28 days followed by galicaftor/navocaftor/ABBV-119 triple combination for 28 days. All other participants will receive the galicaftor/navocaftor/ABBV-119 triple combination or placebo for 28 days. For all study arms, galicaftor, navocaftor, will be given once daily and ABBV-119 twice a day.

Study burden and risks

There may be higher treatment burden for participants inthis trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Contacts

Public
AbbVie Deutschland GmbH & Co. KG

Knollstrasse 50
Ludwigshafen 67061
DE
Scientific
AbbVie Deutschland GmbH & Co. KG

Knollstrasse 50
Ludwigshafen 67061

DE

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

1. Confirmed clinical diagnosis of CF, and genotype homozygous for the F508del CFTR mutation for Cohort 1 and Cohort 3, heterozygous for F508del CFTR mutation and a minimal function mutation for Cohort 2 and Cohort 3.
2. ppFEV1 >= 40% and <= 90% of predicted normal for age, gender, and height (Global Lung Function Initiative [GLI] equations) at Screening.
3. No clinically significant laboratory values at Screening that would pose undue risk for the subject or interfere with safety assessments (per the investigator).
4. Absence of clinically significant abnormality detected on ECG regarding rate, rhythm, or conduction (e.g., QT interval corrected for heart rate using Fridericia's formula [QTcF] should be < 450 msec for males and < 460 msec for females).
5. Stable pulmonary status, i.e., no respiratory infections or exacerbations requiring a change in therapy (including antimicrobials) or causing an acute decline in ppFEV1 of >10% from usual ppFEV1 level within 4 weeks.
6. SwCl at screening visit must be >= 60 mmol/L for Cohort 1 and Cohort 2, and this criteria does not apply to Cohort 3.
7. No history of diseases aggravated or triggered by ultraviolet radiation and no history of abnormal reaction photosensitivity or photoallergy to sunlight, or artificial source of intense light, especially ultraviolet light.

Exclusion criteria

1. Cirrhosis with or without portal hypertension (e.g., splenomegaly, esophageal varices) or history of clinically significant liver disease.

3. History of malignancy within past 5 years (except for excised basal cell carcinoma of the skin with no recurrence, or treated carcinoma in situ of the cervix with no recurrence).
4. Recent (within the past 6 months) history of drug or alcohol abuse that might preclude adherence to the protocol, in the opinion of the investigator.
5. Smoking or vaping tobacco or cannabis products within 6 months before Screening.
6. History of solid organ or hematopoietic transplantation.
7. History of known sensitivity to any component of the study drug.
8. Need for supplemental oxygen while awake, or >2 L/minute while sleeping.
10. Evidence of active SARS-CoV-2 infection. If a subject has signs/symptoms suggestive of SARS CoV-2 infection, they should undergo molecular (e.g., polymerase chain reaction [PCR]) testing to rule out SARS-CoV-2 infection. Subjects who do not meet SARS-CoV-2 infection eligibility criteria must be screen failed and may only rescreen after they meet the SARS-CoV-2 infection viral clearance criteria listed in the protocol.

Study design

Design

Study phase:	2
Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Completed
Start date (anticipated):	28-10-2021
Enrollment:	9
Type:	Actual

Medical products/devices used

Product type:	Medicine

Brand name:	ABBV-119
Generic name:	ABBV-119
Product type:	Medicine
Brand name:	ABBV-2222
Generic name:	Galicaftor
Product type:	Medicine
Brand name:	ABBV-3067
Generic name:	Navocaftor

Ethics review

Approved WMO Date:	23-09-2021
Application type:	First submission
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	28-10-2021
Application type:	First submission
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	04-11-2021
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	30-11-2021
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	10-12-2021
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)

Approved WMO Date:	04-01-2022
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	02-03-2022
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	30-04-2022
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	12-08-2022
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	04-01-2023
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EudraCT	EUCTR2020-005805-25-NL
ClinicalTrials.gov	NCT04853368
CCMO	NL78519.056.21

Study results

Date completed: 10-01-2023

Results posted: 06-06-2024

Summary results
Trial ended prematurely

First publication
04-06-2024